Table 1

Patient demographics and baseline characteristicsa

Demographics and characteristics

Placebo

(n = 50)

Milnacipran

(n = 100)

Total

(N = 150)


Mean age (SD), years

54.0 (8.3)

54.5 (9.3)

54.3 (9.0)

Women, n (%)

48 (96.0)

96 (96.0)

144 (96.0)

Race, n (%)

White

47 (94.0)

96 (96.0)

143 (95.3)

Nonwhite

3 (6.0)

4 (4.0)

7 (4.7)

Mean weight (SD), kg

77.3 (16.7)

80.2 (14.5)

79.2 (15.3)

Mean body mass index (SD), kg/m2

29.0 (6.1)

29.7 (5.2)

29.5 (5.5)

Mean SF-36 PCS score (SD)

41.3 (10.2)

41.6 (8.4)

41.5 (9.0)

Mean SF-36 MCS score (SD)

53.6 (11.3)

53.6 (9.0)

53.6 (9.8)

Mean FIQR total score (SD), range 0 to 100

21.4 (15.8)

19.4 (11.9)

20.1 (13.3)

Mean MAF global fatigue score (SD), range 1 to 50

21.4 (10.4)

20.7 (9.7)

21.0 (9.9)

Mean BPI average pain score (SD), range 0 to 10

2.5 (1.3)

2.3 (1.4)

2.3 (1.4)

Mean VAS pain score (SD), range 0 to 100

19.3 (11.6)

16.6 (9.6)

17.5 (10.3)

Mean VAS pain score (SD), pre-milnacipran exposureb

66.2 (14.7)

65.4 (13.0)

65.7 (13.6)


aBaseline is defined as the randomization visit in this study. BPI = Brief Pain Inventory; FIQR = Revised Fibromyalgia Impact Questionnaire; MAF = Multidimensional Assessment of Fatigue; MCS = Mental Component Summary; PCS = Physical Component Summary; SF-36 = Short Form-36 Health Survey; VAS = Visual Analogue Scale. bBaseline value from lead-in study prior to first milnacipran exposure.

Clauw et al. Arthritis Research & Therapy 2013 15:R88   doi:10.1186/ar4268

Open Data